Published in Obesity and Diabetes Week, March 24th, 2003
"Studies with murine analogs of non-FcR-binding antibodies have shown reduced mitogenicity compared to OKT3," explained K. C. Herold and colleagues at Columbia University.
"In a trial of an FcR nonbinding humanized anti-CD3 mAb hOKT371(Ala-Ala) for treatment of patients with type I diabetes," Herold and coworkers found "significant increases in IL-10 and IL-5 in the serum of 63% and 72% of patients, respectively, and TNF-alpha and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.